Wine Information Council
november 2026
Print

GLP-1 Receptor Agonist and GIP/GLP-1 Receptor Dual Agonist Therapeutics at the Intersection of Alcohol Use Disorder, Obesity, and Cardiometabolic Dysfunction

The co-occurrence of metabolic dysfunction and heavy alcohol consumption contributes substantially to global morbidity, particularly through its impact on liver disease progression. Glucagon-like peptide-1 receptor (GLP1R) agonists and glucose-dependent insulinotropic polypeptide receptor (GIPR)/GLP1R dual agonists, currently approved for the treatment of diabetes and obesity and under investigation for metabolic dysfunction-associated steatohepatitis, are considered for repurposing to reduce alcohol consumption and stabilize metabolic health in heavy-drinking populations. This review summarizes existing evidence, highlights ongoing research, and outlines key unanswered questions regarding this therapeutic potential and the paradigm shift toward metabolic circuit-based interventions in addiction treatment. The dual-target GIPR/GLP1R approach could fill a critical gap for individuals struggling with both heavy alcohol consumption and metabolic dysfunction.
GIPR/GLP1R agonists and related incretin-based therapies, originally developed for diabetes and obesity, may have therapeutic potential for treating alcohol use disorder and alcohol-related metabolic complications. In this review, we examine shared reward, inflammatory, and gut-brain-liver pathways linking harmful alcohol use and metabolic disease. Although early evidence is encouraging, dedicated trials are needed to determine their safety and efficacy in alcohol-related disease.

Additional Info

  • Authors

    Reitz J.; Rosoff D. B.; Pacher P.; Lohoff F. W.

  • Issue

    Periodical: Biol Psychiatry Glob Open Sci - Volume: 6 - Number: 6 - Edition: 20260723

  • Published Date

    november 2026

Related items